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Background: Glioblastoma multiforme (GBM) is the most frequent primary malignant brain tumor in adults. Despite
multimodal therapies, almost all GBM recur within a narrow margin around the initial resected lesion. Thus, novel
therapeutic intensification strategies must target both, the population of dispersed tumor cells around the cavity
and the postoperative microenvironment. Intraoperative radiotherapy (IORT) is a pragmatic and effective approach
to sterilize the margins from persistent tumor cells, abrogate post-injury proliferative stimuli and to bridge the
therapeutic gap between surgery and radiochemotherapy. Therefore, we have set up INTRAGO, a phase I/II
dose-escalation study to evaluate the safety and tolerability of IORT added to standard therapy in newly diagnosed
GBM. In contrast to previous approaches, the study involves the application of isotropic low-energy (kV) x-rays
delivered by spherical applicators, providing optimal irradiation properties to the resection cavity.
Methods/Design: INTRAGO includes patients aged 50 years or older with a Karnofsky performance status of at
least 50% and a histologically confirmed (frozen sections) supratentorial GBM. Safety and tolerability (i.e., the
maximum tolerated dose, MTD) will be assessed using a classical 3 + 3 dose-escalation design. Dose-limiting toxicities
(DLT) are wound healing deficits or infections requiring surgical intervention, IORT-related cerebral bleeding or ischemia,
symptomatic brain necrosis requiring surgical intervention and early termination of external beam radiotherapy (before
the envisaged dose of 60 Gy) due to radiotoxicity. Secondary end points are progression-free and overall survival.
Trial registration: The study is registered with clinicaltrials.gov, number: NCT02104882 (Registration Date: 03/26/2014).Background
Despite recent advances in therapy, Glioblastoma multi-
forme (GBM) is a lethal disease in most cases with a
relatively short overall survival of roughly 15 months
[1,2]. In virtually all cases, GBM recur locally within a
narrow margin (2–3 cm) around the tumor cavity [3-5].
Although GBM are highly invasive and able to migrate
along pre-existing structures such as blood vessels or
white matter tracts [6,7] most (if not all) recurrent tumors
paradoxically grow in close proximity to the resection
margin [8]. Thus, though novel surgical techniques (such
as fluorescence-guided resection) may have improved the* Correspondence: frank.giordano@umm.de
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unless otherwise stated.rates of macroscopic complete resections [9], and ad-
vanced radiotherapy techniques are at hand, no single or
combined approach is sufficient to deplete microscopically
dispersed tumor cells around the tumor cavity.
One of the techniques employed to tackle this challen-
ging feature of GBM is intraoperative radiotherapy (IORT).
IORT allows the delivery of high doses of electrons
(IOERT) or low energy x-rays to the tumor bed while
the surrounding healthy tissue is spared from radiation
due to steep dose gradients [10]. This could lead to instant
sterilization of the cavity surface from remaining tumor
cells and delayed, or impaired, tumor cell proliferation
between surgery and adjuvant therapies in deeper areas
receiving lower doses. Furthermore, high single doses may
elicit local (tumor bed) and systemic (immunogenic)
responses which are not observed in this extent after
conventionally fractionated radiotherapy [11,12].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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studies have shown efficacy of the approach (reviewed in
[13]). However, those pioneering studies were using
IOERT and thus faced classical technical challenges that
come along with a forward-scattering irradiation system
in a setting with cylindrical or spherical tumor cavities.
Postoperative dose reconstructions from the Munster
University group demonstrated that many patients re-
ceiving IOERT exhibited areas of inadequate coverage
(due to inaccurately selected electron energies, inappro-
priate cone sizes or angle errors). As expected, they
found that median and 2-year survival significantly im-
proved with better coverage (MS: 15.2 with adequate
coverage vs. 9.3 months with inadequate coverage; 2-
year survival: 9.3% vs. 0%, p = 0.02) [14,15].
In contrast to the previously used forward-directed elec-
tron beams, the isotropic low-energy X-ray irradiation
source used in the TARGIT (TARGeted Intraoperative
radioTherapy) trial for breast cancer (INTRABEAM
system) [16] is specifically attractive in IORT for brain
tumors, where post-resection cavities are normally of
complex shape. IORT using such spherical applicators
has been proven feasible in pediatric [17] and adult pri-
mary brain tumors [18,19]. However, as there are no
prospective data on safety and tolerability of IORT, we
have designed INTRAGO, a phase I/II study built on
the experience from past trials in several of which
proof-of-principle has been demonstrated.
Objectives
Primary objectives
The primary goal is the definition of the maximal toler-
ated dose (MTD) of spherical isotropic kV-IORT in the
setting of primary GBM.
Secondary objectives
Secondary endpoints are progression-free (PFS) and
overall survival (OS).
Methods/Design
INTRAGO resembles a prospective, open-label, single-
arm dose-escalation study (Figure 1). Dose escalation
will be conducted in a “classical” 3 + 3 manner with
three patients entering each dose level. The decision to
escalate to the next dose level is based on safety assess-
ments after all patients of a cohort have reached month
3 (90 days) after IORT: If no dose-limiting toxicities
(DLTs) occur in a cohort of 3 patients, the next cohort
of 3 patients will be treated at the next higher dose level.
If one of the 3 patients in a cohort experiences a DLT,
an additional cohort of 3 patients will be treated at the
same dose level: If no DLT occurs in the additional co-
hort, dose escalation will continue at the next higher
dose level. Should one or more of the 3 patients in theadditional cohort experience a DLT, the MTD is consid-
ered exceeded and dose escalation will stop. The preced-
ing dose level will then be considered as the MTD. If
two or all of the 3 patients in a cohort experience DLTs,
the MTD will be considered exceeded and the preceding
dose level will be defined as the MTD. If only a total of
3 patients were treated at the potential MTD level, the
potential MTD needs to be confirmed by recruiting an
additional cohort of 3 patients: If none or one of the 6
patients experience a DLT, the MTD will be considered
confirmed. If two or more patients experience a DLT, the
next lower dose level will become the potential MTD. If
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as the MTD. Thus, the MTD is defined as the highest
dose at which one or no DLT will have been observed
among 6 patients.
Patient selection
Patients aged 50 years or older with a Karnofsky per-
formance status (KPS) of at least 50% and a histologi-
cally confirmed (frozen sections) supratentorial unifocal
GBM are included. The tumor location should allow
maximum safe resection. However, patients with tumors
that are likely to be only partially removable are also eli-
gible for the study.
Inclusion criteria
 Histologically confirmed glioblastoma multiforme in
frozen sections
 Age ≥50 years
 Karnofsky Performance Index ≥ 50%
 Written Informed consent
 Adequate birth control (e.g., oral contraceptives)
Exclusion criteria
 Astrocytoma ≤WHO grade III
 Gliomatosis cerebri
 Multifocal lesions
 Infratentorial localization
 Previous cranial radiation therapy (any location)
 Uncontrolled intercurrent illnesses including, but
not limited to, ongoing or active infection or
psychiatric illness/social situations that would limit
compliance with study requirements.
 Contraindications for general anaesthesia
 Bleeding or clotting disorders
 Contraindications for MRI or CT scans
 Pregnant or breastfeeding women
Assessment of the primary objective (Safety)
The primary goal is to determine the MTD, which will
be assessed on the basis of pre-defined dose-limiting
toxicities (DLT).
Two types of DLT are defined:
1) Early DLTs (≤3 weeks after IORT):
– wound infections/wound healing difficulties
requiring surgical intervention
– IORT-related cerebral bleeding or ischemia
2) Early-delayed DLTs (≤3 months after IORT):
– Symptomatic brain necrosis requiring surgical
intervention
– Early termination of EBRT (before the envisaged
dose of 60 Gy) due to radiotoxicityDLTs will be assessed on the basis of clinical presen-
tation (physical examination, KPS, current medication),
imaging studies (MRI) and on the basis of a neuro-
logical assessment using the Late Effects in Normal
Tissues Subjective, Objective, Management and Analytic
(LENT-SOMA) scales defined by the EORTC/RTOG
[20,21].
Evaluation of DLT: clinical exams, medication
Each follow-up visit has to include the most recent med-
ical history, an inspection of the wound/scar and a thor-
ough clinical exam. Episodes of partial or complex seizures
must be documented. Wound healing (and the scar at FU)
is followed with photo documentation. When performing
a physical exam, there should be a specific emphasis on
neurological functions. Specific awareness is advised for
signs of cerebral edema (for example alterations in the
level of consciousness, bradycardia, high blood pressure or
inequality of pupillary size). All current medication and all
changes made in the medication schedule have to be
documented. Detailed information on doses (and dose
changes) has to be only documented for corticosteroids
and anticonvulsants.
Evaluation of DLT: MRI
Each follow-up visit includes MRI with contrast-enhanced
(gadolinium) T1, axial T2 and axial T2-FLAIR sequences.
Ischemic areas can be delineated using perfusion diffusion-
weighted imaging. It is challenging to distinguish early
post-treatment blood–brain barrier permeability impair-
ment from tumor recurrence and “true” brain necrosis.
Here, methods such as Lesion Quotient (LQ), which re-
sembles a ratio of the area delineated in a T2 sequence and
the area of the corresponding contrast-enhanced T1 se-
quence may be applied [22]. In case MRI scans are incon-
clusive, positron emission tomography with amino acid
tracers (such as 18F-fluoro-ethyl-tyrosine) can be offered as
preferential modality.
Management of DLT
Wound infections must be adequately treated, e.g. with
dry absorbent dressing and, in case of positive wound
swabs, systemic antibiotics should be administered match-
ing to the antibiogram. In all cases of wound infection,
blood workup (Complete blood counts, white blood
counts, CRP) and imaging studies should be performed
(CT or MRI) to rule out intracranial abscesses. Each case
of wound infection (our healing difficulty) where conser-
vative therapy fails and surgical revision is required is de-
fined as DLT.
Due to the highly flexible positioning system of the
IORT device, cases of cerebral ischemia or bleeding in-
duced by the applicator are unexpected. Nevertheless,
both were included into the protocol as DLTs and cases
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haemorrhage occur as a consequence of the IORT pro-
cedure (addition to the baseline risk), adequate therapy
is required. Intracranial haemorrhages must be generally
surgically removed if mass effects are exceeding the pri-
mary lesion volume. There is no symptomatic therapy
for arterial or venous ischemia post resection. However,
diffusion-weighted imaging (DWI) should be performed
to document these events during follow-ups.
If radiation necrosis is suspected in MRI scans and no
correlating clinical deterioration is noted, symptomatic
therapy may not be necessary and observation is appro-
priate. For patients with mass effects or neurological
symptoms, treatment options include conservative ther-
apy with corticosteroids or anti-angiogenic substances
(e.g., bevacizumab) or surgical debulking of the necrotic
areas. The decision for either therapy should be made in
interdisciplinary consensus (e.g., in interdisciplinary
tumor boards). If surgery is required, the corresponding
case will be defined as DLT.
All patients will undergo radiochemotherapy and will
present five times per week at the linear accelerators.
Complete blood counts (CBC), a chemistry panel, liver
function tests (LFT) as well as renal function tests (RFT)
are regularly performed to screen for hematotoxicity,
hepatotoxicity or renal toxicity under temozolomide
chemotherapy. Upon intolerance, incompliance or de-
terioration of CBCs, LFTs or RFTs, the therapy with
temozolomide can be discontinued at any time point by
any physician in charge. Any discontinuation of chemo-
therapy for more than 5 consecutive days has to be
documented.
Cranial irradiation can elicit acute (side) effects occur-
ring during treatment or early-delayed effects that appear
within three months after radiochemotherapy [23]. In most
cases, both acute and early delayed side effects largely re-
semble symptoms of mass effects (e.g., headache, nausea,
worsening neurological symptoms), they are responsive to
corticosteroids and they either gradually decrease in sever-
ity during daily radiotherapy (acute effects) or spontan-
eously resolve under cortisol (early-delayed). However, any
case of radiotherapy-associated symptom deterioration
that requires pausing of radiotherapy for more than 5 con-
secutive days has to be documented. If radiotherapy is en-
tirely discontinued due to radiotherapy-associated side
effects before the total dose of 60 Gy is reached, the case
is considered to exhibit a DLT. As for chemotherapy,
EBRT may be discontinued by any physician in charge.
Assessment of secondary end points (efficacy)
Secondary end points are progression-free (PFS) and
overall survival (OS). PFS is defined as the interval (in
days or months) from IORT to the date of first detection
of progressive disease according to updated RANOcriteria [24] or the date of last follow-up. The RANO
working group recommended tight restrictions for
evaluating progression within 12 weeks after radiother-
apy as irradiation transiently increases the permeability
of the (peri)tumoral vasculature which in turn impairs
the validity of MRI scans during this period [25].
In INTRAGO, only cases where new T1-enhancing le-
sions are detected beyond the 80% isodose or new lesions
that are histologically proven to be new manifestations of
GBM are defined as true progression within a timeframe
of 12 weeks after EBRT.
After this period, progressive disease is defined if one
of the following RANO criteria applies:
– New T1-contrast-enhancing lesions outside of
radiation field on decreasing, stable, or increasing
doses of corticosteroids
– Increase by ≥ 25% in the sum of the products of
perpendicular diameters between the first post-
radiotherapy scan, or a subsequent scan with smaller
tumor size, and the scan at 12 weeks or later on
stable or increasing doses of corticosteroids.
– Clinical deterioration attributable to tumor progress
(and not to concurrent medication or diseases)
– Increased T2/FLAIR compared with baseline scan or
best response after initiation of therapy on stable or
increasing doses of corticosteroids.
OS is defined as the interval (in days or months) from
IORT to the date of death from any cause.
Imaging, interventions, follow-up
First visit
Patients that are eligible for the study will be initially ex-
amined and the general medical condition (height, weight,
general condition, Karnofsky index, medical history, medi-
cation) and the neurological (baseline) status (neurological
exam and LENT-SOMA scales) will be assessed. All pa-
tients have to be willing and able to undergo repetitive
MRI scans. Written informed consent must be obtained at
least 24 h prior to surgery and IORT.
Preceding imaging studies
All patients enrolled will receive preoperative MRI im-
aging (minimum 1.5 T) including contrast-enhanced T1-
weighted magnetization-prepared rapid gradient echo
(MP-RAGE) sequences to provide a 3D data set for
image-guided surgery. Advanced imaging (such as perfu-
sion or diffusion weighted imaging) may be performed
at this stage but is not mandatory.
IORT planning, risk structures
The optic nerve(s) (or the chiasm, respectively) and the
brain stem are defined as risk structures and have to be
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located ≤2 cm to a T1-enhancing lesion in pre-operative
MRIs, intraoperative imaging (e.g. intraoperative ultra-
sound or in-room CT/MRI) should be used after re-
moval of the tumor (to account for potential brain
shifts) to document distances to the applicator surface
and to allow dose definition.
Surgery
The resection procedure should be performed as image-
(neuronavigation) guided surgery with techniques that
meet individual center standards and preferences. Resec-
tion techniques may include suction, bi-/monopolar cau-
tery or ultrasound aspiration. Intraoperative application of
5-aminolevulinic acid (5-ALA) can be used to determine
residual tumor tissue. A maximum safe resection approach
is recommended, but not mandatory. Due to the possibility
of liquor accumulation (or retention) around the applica-
tor and subsequent lowering of doses to the target volume
(i.e. the resection cavity wall), ventricular opening during
surgery should be avoided whenever possible.
Frozen section
To establish the diagnosis of GBM, representative tissue
samples have to be sent for histopathological examin-
ation. The frozen section/cryosection procedure can be
performed according to local standards. In case histo-
pathological hallmarks of grade 4 are present, the patient
fulfils all inclusion criteria. If the diagnosis of GBM can
not be reliably established with cryosection or if add-
itional analyses are necessary, IORT must be omitted.
Dose prescription and application of IORT
Following establishment of the diagnosis via frozen section
and after the surgeon defines the macroscopic (or 5-ALA-
delineated) tumor to be satisfactorily removed, IORT will
be prepared. All potentially involved risk structures that
have been defined in pre-operative imaging (see above)
may have displaced consequent to neuro-shifting (i.e.
reduced intracerebral pressure and loss of liquor after
resection) and should be re-identified with intraopera-
tive imaging (ultrasound or in-room CT/MRI).
For the two risk structures (Optical nerve/chiasm and
brain stem), dose constraints of 12 Gy (Optical nerve) and
12.5 Gy (brain stem) are commonly accepted in LINAC-
based EBRT according to the QUANTEC (Quantitative
Analyses of Normal Tissue Effects in the Clinic) recom-
mendations [26]. Since kV-irradiation shows an increased
relative biological effectiveness (RBE) [27], adapted dose
constraints (DMax) of 10 Gy apply for both structures dur-
ing IORT with the (kV-based) INTRABEAM-System.
DMax to these structures are then defined intraoperatively
on the basis of the dose-depth profiles of the correspond-
ing applicator. If the doses to the risk structures at IORT(DIORT) exceed 10 Gy, IORT is technically not feasible and
has to be omitted (screening failure). If any risk structure
is likely to receive a DIORT of > 10 Gy (e.g., the risk struc-
ture has direct contact to the applicator surface) it must
be sufficiently shielded with cut-to-size tungsten-filed sili-
cone shielding strips. Shielding with one layer tungsten-
silicone strips will reduce the DIORT by 90%.
Based on the cavity geometry and adjacent functional
brain areas, the most suitable applicator will be chosen
by the team of surgeons and radiation oncologists (sizes
rage from 1.5- 5.0 cm in 0.5 cm steps). The applicator
will be inserted in the cavity correct positioning and ad-
jacent risk structures will then be again visualized using
intraoperative imaging (ultrasound or in-room CT/
MRI).
Fluids surrounding the surface should be ruled out or
removed. The applicator is then taken out and mounted
onto the INTRABEAM system. Next, the arm and the
source are covered with the sterile drape and the mounted
applicator is again fitted into the resection cavity. Radi-
ation will then be initiated by a radiation oncologist for a
defined time span as calculated by the machine software.
After IORT, surgery will be continued in a regular
fashion without specific additional requirements.
Radiation protection issues
IORT has to be delivered in accordance with federal,
state and/or local regulations on radiation protection.
IORT with the INTRABEAM® System does not require
structural alterations if the operating room is approved
for C-arm fluoroscopy [28].
Early postoperative MRI
Early postoperative MRIs must be performed within a
window of 24–48 h after surgery and must be analyzed in
a standardized assessment. Before contrast application
T1-hyperintense lesions must be used to evaluate residual
blood/heme and T2-TSE, T2-FLAIR, and DWI to evaluate
ischemia. After contrast application, T1-hyperintense
masses or nodules (residual tumor tissue) have to be
quantified and the following has to be documented:
– Complete resection: removal of at least 98% of the
T1-enhancing lesions.
– Subtotal resection: removal of 88-98% of the
T1-enhancing lesions.
– Partial resection: removal of less than 88% of the
T1-enhancing lesions.
Pre-EBRT visit
Before EBRT and concomitant chemotherapy is initiated,
all patients will be re-examined (including a neurological
exam, an update on medication and a re-assessment
based on LENT-SOMA scales) to document changes
Table 2 Exemplary EQD2 values for various IORT doses
(DIORT) to risk organs
DIORT EQD2
3 6 Gy
4 9 Gy
5 13 Gy
6 18 Gy
7 24 Gy
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contraindications for EBRT (such as impaired wound
healing or active infection). Wound healing must be
followed with photo documentation.
External-beam radiotherapy (EBRT) treatment planning
Contrast-enhanced T1- and T2-FLAIR sequences have
to be co-registered with the planning CT scan for radio-
therapy planning. The planning target volume (PTV) is
defined as the peritumoral edema in FLAIR sequences
plus a 2 cm margin. Lenses, retinae, optical nerves and/
or chiasm and brain stem have to be defined as organs
at risk (OAR). The corresponding planning risk volumes
(PRV) are defined as OAR plus a 3 mm safety margin.
For all OAR, point dose (dose to a volume > 0.03 cm3)
constraints apply (Table 1). In case an OAR was pre-
irradiated during IORT (with or without shielding), the
dose applied to the OAR during IORT (DIORT) has to be
converted into an dose that is equivalent to a 2 Gy frac-
tionation scheme (EQD2) using an α/β ratio of 2 and
considering an RBE of 1.5 as follows (Table 2 gives ex-
emplary DIORT and EQD2 values):
EQD2 ¼ 1:5 • DIORT• DIORT þ α=βð Þ= 2þ α=βð Þ
¼ 1:5 • DIORT• DIORT þ 2ð Þ=4
Adequate target volume coverage should be consid-
ered by ensuring that 95-107% of the prescribed dose is
received by 95% of the PTV. Both, 3D-CRT or IMRT
may be applied, beam energies must at least be 6 MV. A
total dose of 60 Gy delivered in 30 fractions (2 Gy/
fraction) will be applied to the PTV. In case the PTV in-
cludes a PRV which would in consequence not receive a
dose within the given constraints, a specific risk-organ
PTV (PTV-R) has to be delineated to allow separate
dose reconstruction.
EBRT
EBRT must be initiated within 4 weeks after surgery and
IORT. All patients will receive five fractions of radio-
therapy per week on a conventional linear accelerator
(LINAC) with thermoplastic mask fixation. Pausing of
radiotherapy is allowed for maximum 5 consecutive
days. During EBRT, patients are routinely seen once toTable 1 Point dose constraints (dose to a volume> 0.03 cm3)
for OAR
Risk organ Maximum point dose (EQD2)
Lenses 7 Gy
Retinae 50 Gy
Optical nerves/chiasm 55 Gy
Brain stem 66 Gytwice weekly by physicians and evaluated for adverse
reactions.
Concomitant chemotherapy
During EBRT, all patients will receive concomitant
temozolomide-based chemotherapy with a total oral
dose of 50 mg/m2/d five times per week (on radiother-
apy treatment days). Chemotherapy will be initiated at
the first day of radiotherapy and will be continued until
the last day of radiotherapy. Discontinuation of chemo-
therapy is allowed for maximum 5 consecutive days.
Adjuvant chemotherapy
Four weeks after radiochemotherapy, adjuvant chemo-
therapy with temozolomide is initiated if the patients do
not exhibit contraindications (low RBC, WBC and/or
platelet counts, previous adverse reactions). The doses
will be selected in accordance with the Stupp-protocol
(150–200 mg/m2/d temozolomide, day 1–5 every
28 days) [2]. At least six cycles of chemotherapy should
be applied. If a patient tolerates the cycling chemother-
apy with temozolomide well, additional cycles may be
applied.
Post-EBRT follow-ups
Follow-up visits after radiochemotherapy will be sched-
uled quarterly. Each visit is preceded by brain MRI im-
aging studies (contrast-enhanced T1, T2 and T2-FLAIR
sequences). Advanced imaging (diffusion- and perfusion-
weighted sequences) is optional. The MRI scans are evalu-
ated by a board-certified radiologist or neuroradiologist in
accordance to updated RANO criteria (see above). Follow-
up visits also include an assessment of the general medical
condition (height, weight, general condition, Karnofsky
index, medical history, medication) and the neurological
status (neurological exam and LENT-SOMA scales).
Serious adverse events
Treatment-emergent (i.e. IORT-related) events that are
fatal, life threatening or classified as LENT-SOMA grade
IV toxicity resemble a serious adverse event (SAE) and
have to be documented. In case of death an autopsy will
be pursued.
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INTRAGO is approved by the local ethics committee
(Medical Ethics Commission II of the Faculty of Medi-
cine Mannheim, University of Heidelberg; 2013-548S-
MA) and the Federal Office of Radiation Protection
(Z 5-22462/2-2013-063). The trial is registered with
clinicaltrials.gov, number: NCT02104882.
Discussion
We here present the first dose-finding study on low-
energy intraoperative radiotherapy for glioblastoma mul-
tiforme. Previous approaches used forward-directed elec-
tron beams that only inconsistently provided sufficient
target volume coverage, leading to inconsistency in re-
ported outcomes [15,29-37]. Within INTRAGO, the
spherically irradiating devices of the INTRABEAM sys-
tem are used to enable geometry-optimized IORT. This
may for the first time enable sufficient dose delivery to
the resection cavity and to remaining tumor cells.
On may argue that there is no benefit of further dose
escalation after resection due to failure of trials involving
dose escalation or additional radiosurgery to the tumor
bed [38]. We challenge this conclusion on the basis of
two facts that involve the (crucial) time between surgery
and adjuvant therapy:
First, it is known that the mean doubling time of a
GBM stem cell may be as fast as 24 hours and conse-
quently, the waiting time for EBRT correlates with over-
all survival [39,40]. IORT is embedded in the surgical
removal of the mass and thus will likely prevent and/or
slow down this exceptionally fast tumor growth in this
timeframe. Second, GBM growth shows dose-dependency
as early studies showed that doses of at least 50 Gy are re-
quired to improve overall survival [41,42]. In the RTOG
98–03 trial, patients treated with 66 Gy showed the worst
(11.6 months) and those receiving 84 Gy showed the best
survival rates (19.3 months) without increased rates of
toxicities [43]. Of note, this study was conducted with ra-
ther “old” techniques and in the era of more advanced
functional imaging (such as PET) and irradiation tech-
niques (intensity-modulated radiotherapy) dose-escalation
may be even more safely and efficiently conducted [44].
We think that the reason why several other dose-
escalation trials were failing is likely to be related to
processes occurring during the time between surgery
and adjuvant therapy: any wounded site creates a spe-
cific stimulatory environment to promote healing,
which inadvertently provides remaining cancer cells
with strong pro-proliferative, pro-migratory and anti-
apoptotic stimuli [45,46]. In breast cancer, it has been
shown that this unwanted response of the injured
microenvironment can be attenuated with IORT [47].
This had direct consequences on the clinical outcome:
patients that received IORT in a sequential operation, i.e. after the first surgery confirmed the diagnosis (‘post-
pathology’ cohort) showed higher local recurrence rates
(5.4%) compared with patients that received IORT dur-
ing first surgery (2.1%; ‘pre-pathology’ cohort) [16].
Whether or not traumatic brain injury has a similar
strong influence on GBM cell proliferation post surgery
as observed in breast cancer has not been demonstrated
yet. However, as the injured brain is very well known to
respond with an impressive cytokine cocktail that effi-
ciently promotes astrocytic activation and proliferation
[48-50], we believe that similar (and, regarding survival,
likely highly beneficial) quenching of the tumor micro-
environment may be achievable after IORT for GBM.
Symptomatic brain necrosis requiring surgical inter-
vention was defined as DLT. Brain necroses appeared in
multiple IOERT trials and they mostly correlated with
improved survival [29]. This, together with the fact that
bevacizumab is a novel and effective option to conserva-
tively treat brain necroses [51] was prompting us to only
consider brain necroses as a DLT if they become symp-
tomatic and if they require surgery. However, although
we do expect cases of brain necrosis, highly elevated
rates are less likely as it is well known that the irradiated
volume of brain is the key determinant for this side ef-
fect [52]. The device used for IORT in INTRAGO uses
low-energy (kV) photons that show exponential attenu-
ation along their path [53]. Logically, the area receiving
high(est) doses is a margin of maximum 1–1.5 cm width
around the tumor cavity (IORT with 40 Gy surface dose
at dose level III would result in doses of 12 Gy at 1 cm,
8 Gy at 1.5 cm and 4 Gy in 2 cm depth), which is a vol-
ume that is eventually not large enough to become clin-
ical apparent.
INTRAGO is the first prospective IORT study in the
era of temozolomide. The alkylating agent has become a
crucial part of standard treatment after the pivotal
EORTC/NCIC study showed a considerable improve-
ment of both overall and long-term survival rates if the
substance is added to radiotherapy and given as adjuvant
chemotherapy [1]. It is believed that the increased rates
of blood–brain barrier permeability impairments that
are seen after radiochemotherapy (and which are often
misinterpreted as progressive disease) are predominantly
caused by temozolomide [25,54]. This abnormal local re-
actions together with pre-clinical investigations point to
additive and/or even synergistic activity of both modal-
ities and it will be of specific interest to see whether
IORT can further modulate these interactions [55,56].
In conclusion, INTRAGO is the first dose-finding
study on low-kV-IORT for newly diagnosed GBM in the
temozolomide era with optimized geometry adaptation.
It should provide a robust basis for subsequent random-
ized (phase II or III) trials, in which superiority over
standard treatment must be tested.
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